Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide

dc.TypeArticlept_BR
dc.contributor.authorMelo, Andreia Cristina de
dc.contributor.authorBraga, Antonio
dc.contributor.authorMora, Paulo Alexandre Ribeiro
dc.contributor.authorRodrigues, Angélica Nogueira
dc.contributor.authorAmim Junior, Joffre
dc.contributor.authorRezende Filho, Jorge
dc.contributor.authorSeckl, Michael
dc.date.accessioned2021-12-15T16:36:45Z
dc.date.available2021-12-15T16:36:45Z
dc.date.issued2019
dc.descriptionp. 28-37. : il. p&b.
dc.description.abstractGestational trophoblastic neoplasia (GTN) is a rare tumor that originates from pregnancy that includes invasive mole, choriocarcinoma (CCA), placental site trophoblastic tumor and epithelioid trophoblastic tumor (PSTT/ETT). GTN presents different degrees of proliferation, invasion and dissemination, but, if treated in reference centers, has high cure rates, even in multi-metastatic cases. The diagnosis of GTN following a hydatidiform molar pregnancy is made according to the International Federation of Gynecology and Obstetrics (FIGO) 2000 criteria: four or more plateaued human chorionic gonadotropin (hCG) concentrations over three weeks; rise in hCG for three consecutive weekly measurements over at least a period of 2 weeks or more; and an elevated but falling hCG concentrations six or more months after molar evacuation. However, the latter reason for treatment is no longer used by many centers. In addition, GTN is diagnosed with a pathological diagnosis of CCA or PSTT/ETT. For staging after a molar pregnancy, FIGO recommends pelvic-transvaginal Doppler ultrasound and chest X-ray. In cases of pulmonary metastases with more than 1 cm, the screening should be complemented with chest computed tomography and brain magnetic resonance image. Single agent chemotherapy, usually Methotrexate (MTX) or Actinomycin-D (Act-D), can cure about 70% of patients with FIGO/World Health Organization (WHO) prognosis risk score ≤ 6 (low risk), reserving multiple agent chemotherapy, such as EMA/CO (Etoposide, MTX, Act-D, Cyclophosphamide and Oncovin) for cases with FIGO/WHO prognosis risk score ≥ 7 (high risk) that is often metastatic. Best overall cure rates for low and high risk disease is close to 100% and > 95%, respectively. The management of PSTT/ETT differs and cure rates tend to be a bit lower. The early diagnosis of this disease and the appropriate treatment avoid maternal death, allow the healing and maintenance of the reproductive potential of these women.
dc.identifier.citationMELO, Andreia Cristina de et al. Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide. World J Clin Oncol, v. 10, n. 2, p. 28-37, feb. 2019.
dc.identifier.issn2218-4333
dc.identifier.urihttp://sr-vmlxaph03:8080/jspui/handle/123456789/4791
dc.publisherWorld J Clin Oncolpt_BR
dc.subjectDiagnósticopt_BR
dc.subjectDiagnosispt_BR
dc.subjectGravidezpt_BR
dc.subjectPregnancypt_BR
dc.subjectNeoplasiaspt_BR
dc.subjectNeoplasmspt_BR
dc.subjectDoença Trofoblástica Gestacionalpt_BR
dc.subjectGestational Trophoblastic Diseasept_BR
dc.titleChallenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwidept_BR

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide..pdf
Size:
480.36 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.6 KB
Format:
Item-specific license agreed upon to submission
Description: